Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Cloranolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.52 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.47 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cloranolol SCHEMBL80493 | 0.97 | SLC2A1 (0.62) | SLC2A1KMT2AMEN1HTTADRB2 | |
| Cloranolol SCHEMBL80494 | 0.97 | SLC2A1 (0.62) | SLC2A1KMT2AMEN1HTTADRB2 | |
| Cloranolol SCHEMBL1230787 | 0.96 | KMT2A (0.63) | SLC2A1KMT2AMEN1HTTADRB2 | |
| Cloranolol SCHEMBL1230788 | 0.96 | KMT2A (0.63) | SLC2A1KMT2AMEN1HTTADRB2 | |
| Bupranolol SCHEMBL29518497 | 0.85 | L3MBTL1 (0.63) | SLC2A1KMT2AMEN1HTTADRB2 | |
| Bupranolol SCHEMBL123717 | 0.85 | L3MBTL1 (0.63) | SLC2A1KMT2AMEN1HTTADRB2 | |
| Bupranolol SCHEMBL34061 | 0.85 | L3MBTL1 (0.63) | SLC2A1KMT2AMEN1HTTADRB2 | |
| Bupranolol SCHEMBL2497819 | 0.85 | L3MBTL1 (0.63) | SLC2A1KMT2AMEN1HTTADRB2 | |
| Bupranolol SCHEMBL6508337 | 0.85 | L3MBTL1 (0.63) | SLC2A1KMT2AMEN1HTTADRB2 | |
| Bupranolol SCHEMBL348362 | 0.84 | L3MBTL1 (0.65) | SLC2A1KMT2AMEN1HTTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| EP-1303306-B1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND BETA-ADRENERGIC ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORP (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050215537-A1 | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | PHARMACIA CORPORATION | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215537-A1 | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | ADRB1, ADRB2, ADRB3 | ACHE 2465/4885CHRM1 580/4885SLC6A2 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.